Strüngmann Family Office Athos Acquires Stake in Doctolib

Key Takeaways

• Athos bought minority stake in Doctolib via secondary round
• Deal valued Doctolib at €3.6 billion, below 2022 level
• Doctolib posted €422 million revenue, first profitability in 2024
• 400,000 providers and 25 million German patients use platform
• Investment signals growing family‑office interest in European health tech

Pulse Analysis

Athos' entry into Doctolib reflects a strategic shift for single‑family offices toward high‑growth, non‑core sectors such as digital health. By purchasing shares from early investors rather than providing new capital, Athos capitalised on a secondary‑market discount, securing exposure to a platform that has already demonstrated robust European traction. This approach mirrors a broader trend where wealthy families diversify beyond traditional assets, leveraging deep pockets to acquire stakes in companies poised for long‑term value creation without the dilution risks of primary funding rounds.

Doctolib's operational metrics reinforce its status as a cornerstone of Europe’s health‑tech ecosystem. With 400,000 paying providers—including roughly 100,000 in Germany—and 25 million active patient accounts, the platform commands a sizable share of the appointment‑booking market. Its 2024 annualised revenue of €422 million, a near‑33 % year‑on‑year increase, marked the first profitable year, signalling that scale efficiencies and subscription‑based pricing are finally offsetting earlier investment burn. The company’s ability to sustain growth while achieving profitability positions it as an attractive target for both strategic and financial investors seeking stable cash flows in a regulated industry.

The broader implication for the European digital‑health landscape is twofold. First, the transaction validates the sector’s maturity, encouraging more family offices and sovereign wealth funds to allocate capital alongside traditional venture firms. Second, the €3.6 billion valuation, despite being lower than the 2022 peak, suggests that secondary market corrections can create entry points for long‑term investors, potentially accelerating consolidation as larger players acquire complementary technologies. As health systems continue digitising, platforms like Doctolib are likely to become pivotal infrastructure, driving further investment interest and shaping the future of European healthcare delivery.